Table Of Content
How to Buy Ozempic (Novo Nordisk) Stock
Buying shares of Novo Nordisk — the pharmaceutical company behind Ozempic — is accessible through most mainstream brokerage platforms.
Whether you're a long-term investor or looking to tap into the surging interest in weight-loss and diabetes treatments, here’s how to get started:
-
1. Choose a Brokerage That Offers Foreign Stocks or ADRs
Novo Nordisk is a Danish company traded on the Copenhagen Stock Exchange under the symbol NOVO-B, but U.S. investors can easily buy it through American Depositary Receipts (ADRs) listed as NVO on the NYSE.
Major platforms like Charles Schwab, Fidelity, Robinhood, and Interactive Brokers all support trading ADRs.
For example, Robinhood allows you to search “NVO” just like any U.S. stock and add it to your watchlist or portfolio.
In addition, some brokers—like Interactive Brokers—give you access to the actual foreign shares (if you're interested in holding them directly).
-
2. Create and Fund Your Account
Once you’ve selected your broker, go ahead and set up your investment account by submitting personal details like your Social Security number and income level (required for compliance).
After the account is verified, connect your bank and transfer funds.
Let’s say NVO is trading at $125 per share and you’re aiming to invest around $1,000.
You can either buy eight full shares or use a broker like Robinhood or Fidelity that supports fractional shares, allowing you to invest $1,000 precisely—even if it’s not a round number of shares.
-
3. Research Novo Nordisk’s Business and Ozempic’s Impact
Before buying, take time to understand what’s driving Novo Nordisk’s growth. Ozempic isn’t just a diabetes treatment — it’s part of a larger trend in GLP-1 drugs, which are also being used off-label for weight loss.
Here are a few areas worth investigating:
Ozempic sales growth: The drug has been a blockbuster, with global demand rising sharply.
Pipeline and competition: Novo’s Wegovy is also in demand, but competitors like Eli Lilly’s Mounjaro are gaining attention .
Financial health: Look into revenue, profit margins, and free cash flow using platforms like Yahoo Finance or Morningstar.
Long-term outlook: Consider how healthcare policies, obesity trends, and global approvals may influence sales.
If you’re bullish on the global demand for GLP-1 drugs, Novo Nordisk could play a significant role in your portfolio.
-
4. Place a Buy Order
Now that you’ve done your research, log into your brokerage account and search for NVO (for U.S. investors). Most platforms will give you the option to:
Market order: Executes your buy immediately at the current price.
Limit order: Lets you set a maximum price you’re willing to pay.
Recurring order: Useful if you want to invest consistently over time (e.g., monthly).
For example, if you believe NVO is slightly overvalued at $130 but would buy it at $120, you could set a limit order at that price and wait for a dip.
-
5. Track Your Investment Over Time
After purchasing Novo Nordisk stock, you’ll want to monitor developments that could affect its share price — including Ozempic approvals, sales numbers, and healthcare policy changes.
Many platforms let you set up alerts for quarterly earnings, product updates, and analyst upgrades or downgrades.
For example, if the FDA expands Ozempic’s approved use cases, that news may trigger significant stock movement.
How to Invest in Novo Nordisk (Ozempic) Indirectly
If you’re interested in the success of Ozempic but don’t want to buy Novo Nordisk stock directly, there are several indirect ways to invest:
-
Invest in ETFs That Hold Novo Nordisky
A simple way to gain indirect exposure is through exchange-traded funds (ETFs) that include Novo Nordisk (NVO) in their holdings. Since Novo is a large-cap pharmaceutical company, it's often a top holding in health-focused and international ETFs.
Some examples include:
iShares MSCI Denmark ETF (EDEN) – Offers country-specific exposure, with Novo Nordisk typically as its largest component.
iShares Global Healthcare ETF (IXJ) – A broader play on global pharma, including Novo, Eli Lilly, and Johnson & Johnson.
SPDR MSCI ACWI ex-US ETF (CWI) – For those seeking non-U.S. large-cap exposure, with partial weight in Novo.
By investing in these ETFs, you’re not only tapping into Ozempic’s growth but also gaining exposure to other healthcare and biotech leaders
-
Invest in Competitors or GLP-1 Focused Drugmakers
Ozempic is part of the rapidly expanding GLP-1 drug market, and Novo Nordisk isn’t the only player. If you're interested in the broader trend rather than a single stock, consider investing in other companies involved in similar treatments.
For instance:
Eli Lilly (LLY) – Maker of Mounjaro, a major competitor to Ozempic in both diabetes and obesity treatment markets.
Amgen (AMGN) – Developing its own GLP-1 weight-loss drug and has gained investor attention due to trial results.
Pfizer (PFE) – Although it halted development of one weight-loss drug, it continues to explore alternatives in this space.
These companies offer different risk-reward profiles and may complement or hedge your exposure to Novo.
-
Use Mutual Funds or Managed Portfolios with Novo Exposure
Another hands-off approach is investing through mutual funds or robo-advisors that already hold Novo Nordisk stock as part of their portfolio. This method works well if you prefer diversified, professionally managed strategies.
For example:
Vanguard International Growth Fund (VWIGX) often includes Novo among its top holdings, thanks to its strong fundamentals and global presence.
Schwab Intelligent Portfolios or Betterment may allocate a portion to healthcare-focused or European equity ETFs that include Novo, based on your risk profile.
This route is ideal for investors who want long-term exposure to the pharmaceutical and biotech sectors without having to pick individual stocks themselves.
Buying Ozempic (Novo Nordisk) Stock: Pros & Cons
Ozempic has fueled investor interest in Novo Nordisk, but buying the stock comes with both growth potential and some cautionary factors:
Pros | Cons |
|---|---|
Strong Ozempic Sales Growth | Regulatory Risk |
Consistent Profitability | Competitive Pressure |
Global Market Expansion | Valuation Concerns |
GLP-1 Pipeline Development | Supply Chain Constraints |
- Strong Ozempic Sales Growth
Ozempic sales have surged due to rising global demand for both diabetes and weight-loss treatments, positioning Novo as a market leader.
- Consistent Profitability
Novo Nordisk has a strong track record of profitability and efficient operations, which supports long-term investor confidence.
- Global Market Expansion
The company continues to expand Ozempic’s availability across international markets, boosting future revenue potential.
- Pipeline of GLP-1 Drugs
Novo is investing in next-gen treatments like CagriSema, which may further extend its leadership in obesity and diabetes care.
- Regulatory Risk
Ozempic’s approval for different uses varies by country, and future regulatory hurdles could impact growth expectations.
- Competitive Pressure
Rivals like Eli Lilly’s Mounjaro and upcoming GLP-1 drugs may erode Novo’s market share over time.
- Valuation Concerns
As demand for Ozempic has exploded, the stock's price has risen significantly—leading some analysts to question whether it’s overvalued.
- Supply Chain Constraints
Recent surges in demand have led to production challenges, with some reports of shortages impacting global availability.
FAQ
While Ozempic plays a major role, the stock is also influenced by drugs like Wegovy, Rybelsus, pipeline updates, and global regulatory developments. Broader healthcare trends can also impact valuation.
Novo is considered a strong long-term play due to its innovation in diabetes and obesity treatments, financial strength, and global reach. However, risks like regulation and competition still apply.
Yes, ADRs like NVO are eligible for inclusion in retirement accounts including IRAs. Be sure your brokerage supports international equities within retirement plans.
You may be subject to foreign withholding tax on dividends, depending on U.S.–Denmark tax treaties. Consult a tax professional or brokerage resources to understand the impact.
For most U.S. investors, ADRs are more accessible and liquid. Direct purchase of foreign shares may come with currency conversion, higher fees, and lower convenience.
You can explore trusted platforms like Morningstar, Seeking Alpha, and Yahoo Finance for financials, analyst opinions, and stock forecasts. Novo’s own investor relations site is also helpful.
Yes, many brokers like Fidelity, Schwab, and Robinhood offer fractional shares, letting you invest in NVO without buying a full share.
The U.S. ADR ticker is NVO, listed on the New York Stock Exchange. In Denmark, the stock trades as NOVO-B on the Copenhagen Stock Exchange.
Quarterly earnings reports published on Novo Nordisk’s investor site detail drug-specific sales. Financial news outlets like Reuters and Bloomberg also provide ongoing coverage.
Key risks include patent expiration, growing competition from Eli Lilly, supply shortages, and regulatory changes that could impact the availability or pricing of Ozempic.
